Does Age Affect Care Outcomes in Patients With COPD on NIV?
Health-related quality of life (HRQOL) did not differ significantly between younger and older patients with chronic obstructive pulmonary disease (COPD) suffering from chronic hypercapnic respiratory failure receiving long-term noninvasive ventilation (NIV), despite a higher comorbidity burden in older patients.
METHODOLOGY:
Researchers conducted a prospective, observational study to investigate the differences in HRQOL between younger and older patients with COPD and chronic hypercapnic respiratory failure receiving long-term NIV.
They enrolled 237 patients between June 2015 and October 2021, with 41.8% enrolled as inpatients and 58.2% as outpatients, categorized into two age groups: younger (< 65 years) and older (≥ 65 years).
HRQOL was assessed using the severe respiratory insufficiency (SRI) questionnaire, and factors affecting HRQOL — including anemia, autonomy impairment, exacerbation history, and comorbidities — were evaluated.
A five-tier scale categorized autonomy impairments by severity with level 1 denoting minor impairments and level 5 indicating the most severe loss of independence or ability, which pose substantial challenges for nursing care.
TAKEAWAY:
No significant differences were found in SRI summary scores between age groups, despite older patients having a significantly higher burden of comorbidities (P = .014).
Exacerbation frequency had a significant negative impact on SRI scores in both younger and older patients.
Anemia was linked to a significant reduction in SRI scores only in younger patients, in whom it was more prevalent (29.1% vs 17.5%; P = .045).
Any level of autonomy impairment negatively affected HRQOL in younger patients, whereas only higher levels (level of care ≥ 2) affected HRQOL in older patients.
IN PRACTICE:
'Understanding of COPD with comprehensive care plans that address both medical and functional aspects, patient outcomes, and HRQOL might be improved,' the authors wrote.
SOURCE:
This study was led by Maximilian Zimmermann, Department of Pneumology, Witten/Herdecke University, Cologne, Germany. It was published online on June 7, 2025, in BMC Pulmonary Medicine.
LIMITATIONS:
The heterogeneity of the study cohort, due to inclusion of both inpatients and outpatients, may have led to variability in clinical status and care settings. Additionally, patients were eligible after 1 month of NIV, most had been on long-term therapy prior to inclusion, which could have influenced the assessment of HRQOL. Because the study was conducted at a single center, the results may not be applied to broader populations.
DISCLOSURES:
This study did not receive any research funding. The authors reported having no relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Bain Capital-backed Heartflow eyes $1.3 billion valuation in US IPO
(Reuters) -Healthcare firm Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its initial public offering in the United States. The Mountain View, California-based company, backed by private investment firm Bain Capital, is aiming to raise as much as $212.5 million by offering 12.5 million shares priced between $15 and $17 apiece. Heartflow's listing comes more than three years after its previous attempt to go public through a blank-check merger fell through. Morgan Stanley and Piper Sandler are the lead underwriters for the offering. Heartflow will list on the Nasdaq under the trading symbol "HTFL".
Medscape
25 minutes ago
- Medscape
Enterosorbent Gel Shows Efficacy in IBS
TOPLINE: Silicolgel, a colloidal silicic acid enterosorbent, was generally safe and well tolerated, and it significantly reduced symptom severity in adults with irritable bowel syndrome, with efficacy being observed in both patients with predominant diarrhoea (IBS-D) and those with mixed bowel habits (IBS-M). METHODOLOGY: Researchers conducted a randomised controlled trial to assess the efficacy, safety, and tolerability of silicolgel in patients with IBS-D and IBS-M. They included 120 adults (mean age, 36.9 years; 66% women) with IBS-D or IBS-M across four regional health centres in Ukraine between March 15, 2023, and August 31, 2023, with a score on the IBS Severity Scoring System (IBS-SSS) of 100-400 points. Patients were randomly assigned to receive either 15 mL of silicolgel (n = 60) or placebo (n = 60) three times daily for 4 weeks, followed by a 4-week no-medication observation phase to assess the return of symptoms. The primary outcome was a reduction in IBS-SSS scores by ≥ 50 points after 4 weeks of treatment, indicating a clinically meaningful improvement in symptoms. Patients used daily diaries to track bowel habits, IBS symptoms (including abdominal pain and bloating), and quality of life. TAKEAWAY: After 4 weeks, the proportion of patients achieving at least a 50-point reduction in the IBS-SSS score was significantly higher in the silicolgel group than in the placebo group (91.67% vs 20%; relative risk [RR], 4.58; P < .0001). The silicolgel group showed a significantly greater decrease in the mean IBS-SSS score, from 255.62 at baseline to 92.75 after 4 weeks, than the placebo group that showed a change from 254.42 at baseline to 257.58 after 4 weeks (P < .001). Among patients with IBS-D and IBS-M, those on silicolgel vs placebo achieved the primary outcome (RR, 4.77 and 4.44, respectively; P < .0001 for both). Significant reductions in mean severity scores were noted for IBS symptoms from baseline to week 4 with silicolgel. All adverse events were mild and non-serious, noted at one site, and found unrelated to treatment, with no treatment discontinuations observed. IN PRACTICE: "Silicolgel is a widely available and affordable enterosorbent treatment, providing safe and effective relief of symptoms in patients with IBS-D and IBS-M. Based on these findings, its use should be considered more widely for frontline therapy of IBS-D and IBS-M," the authors of the study wrote. SOURCE: This study was led by O. Kuzminska, Chernivtsi Hospital of Emergency Medical Care, Chernivtsi, Ukraine. It was published online on July 25, 2025, in Neurogastroenterology & Motility. LIMITATIONS: Silicolgel is not absorbed and works locally in the gut, beginning to exert its effect immediately. Thickeners could not be used in the placebo because they affect the gut, so the viscosity of the placebo was a white, watery solution. Additionally, the treatment was limited to 28 days as silicolgel's licence permits a continuous dosing period of not more than 4 weeks. DISCLOSURES: This study was supported by FW Medical Ltd, the owner of silicolgel, and Delta Medical LLC, the distributor of silicolgel in Ukraine. They had no direct involvement in the study. One author reported being a consultant for the owner company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
25 minutes ago
- Medscape
Ultra-Low-Dose CT Outperforms Chest X-Rays in Paediatric CF
TOPLINE: At similar radiation doses, ultra-low-dose CT (ULDCT) achieved superior image quality using AI-enhanced iterative reconstruction than chest x-rays for assessing cystic fibrosis-related lung disease in children. About 88% of healthcare professionals reported greater confidence in diagnosing cystic fibrosis-related lung disease when using CT images rather than x-rays. METHODOLOGY: Researchers recruited 75 observers (50 radiographers and 25 radiologists) from 24 countries who assessed the image quality of 10 randomly selected paired ULDCT and chest x-ray images from a cohort of 70 children with cystic fibrosis (age, 3-18 years). ULDCT scans were acquired at 80 kV, 10 mA with deep learning iterative reconstruction to produce images at lower radiation doses. Image quality analysis was performed using an image quality survey that was organised into four distinct sections and hosted on DetectED-X. Observers rated images on the basis of a 0-4 scale rating system for quality and a 5-point Likert scale for diagnostic confidence evaluation. TAKEAWAY: Overall, 88% of observers reported higher levels of confidence with ULDCT (P < .05) than with chest x-rays (P < .001) in diagnosing cystic fibrosis-related lung disease, with comparable radiation doses between the two modalities. The combined visual grading analysis indicated higher image quality for ULDCT images, with radiologists rating ULDCT significantly superior to chest x-rays for lung pathology detection (area under the curve, 0.63; P = .03). Overall, 69% vs 50% of observers rated the quality of ULDCT images vs chest x-rays as either adequate (score 3) or better than needed (score 4). No significant differences in anatomic visualisation were observed between ULDCT and chest x-rays (P = .306). IN PRACTICE: "ULDCT provides superior IQ [image quality] compared to CXR [chest x-rays] in CwCF [children with cystic fibrosis], while maintaining comparable radiation doses," the authors wrote. "ULDCT also significantly improves diagnostic confidence, highlighting its potential as a viable alternative to CXR," they concluded. SOURCE: This study was led by Niamh Moore, University College Cork, Cork, Ireland. It was published online on July 25, 2025, in European Radiology. LIMITATIONS: Chest x-rays were used as a comparator instead of conventional dose CT, and exposures were not patient specific for ethical reasons. The recruitment of observers from different research hubs having varying illumination levels affected image quality ratings. Additional limitations included the small sample size and selection bias. DISCLOSURES: This study received open access funding provided by the IReL Consortium. One author reported having a relationship with DetectED-X. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
